Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dr. Reddy's
Pharma
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Novartis is mitigating a potential threat from the BIOSECURE Act. A Neurocrine drug from Takeda posted a trial win. Enhertu nears a HER2-low readout.
Angus Liu
Apr 26, 2024 5:45am
Dr. Reddy's recalls 6 lots of PKU drug due to potency problems
Apr 25, 2024 8:25am
Big Pharma CEOs in China, AstraZeneca, WuXi—Fierce Pharma Asia
Mar 29, 2024 10:10am
Big Pharma deal spree, China plans and more—Fierce Pharma Asia
Jan 5, 2024 8:44am
FDA slams trio of Indian drugmakers with Form 483 filings
Jan 3, 2024 9:40am
WuXi, Daiichi-Novartis, Merck KGaA-Abbisko—Fierce Pharma Asia
Dec 8, 2023 8:13am